To battle those disruptions, AbbVie, maker of three migraine treatment options, launched a contest this year to provide support for people whose migraines create obstacles in reaching their ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its ...

A splashy recent acquisition by the company might not be panning out. Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary ...

(Bloomberg) -- AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $ ...

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine ...

1-2 NORTH CHICAGO, Ill., Nov. 14, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced 20 winners of the inaugural AbbVie Migraine Career Catalyst Award™ contest, a first-of-its-kind contest ...

An AbbVie schizophrenia drug acquired as part of a multi-billion dollar deal has failed two mid-stage studies, dealing a setback to the company’s plans to compete with a Bristol Myers Squibb ...

Emraclidine was part of AbbVie's acquisition of Cerevel last year, which also included Tavapadon, which reported positive Phase 3 data. Bristol's Cobenfy is now poised to dominate the ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham from Citi reiterated a Buy rating on the stock and has a $ ...

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent $9 billion ...